Medicare drug plans must now disclose hidden PBM costs and pick the cheapest bid

What it does

This bill requires Medicare Part D and Medicare Advantage plans to use a standardized, transparent bidding process when selecting pharmacy benefit managers (PBMs), and mandates that plans choose the lowest-cost bid unless they can justify selecting a higher-cost option to advance specific program goals. It also requires PBMs to guarantee their cost projections and imposes new auditing, monitoring, and public reporting requirements on plans to ensure actual drug costs match what was promised in bids. Similar transparency rules apply to commercial health plans under ERISA.

Why we flagged it

The bill's core mechanism is a mandatory competitive bidding process with standardized cost disclosure, auditing, and enforcement—designed to expose and constrain PBM pricing opacity and hidden rebate capture. This is regulatory transparency and cost accountability, not a subsidy or carve-out.

What the text implies

• PBMs may respond by consolidating with larger health plans or insurers to avoid competitive pressure, potentially reducing independent PBM options and increasing vertical integration in drug distribution.
• The 10% cost-variation tolerance threshold (subsection j(2)(C)(ii)) creates a safe harbor for PBMs; variations within that band face no penalty, potentially allowing systematic cost overruns up to the cap.
• Real-time cost-sharing tools (subsection j(1)(B)) require PBMs to disclose net-of-rebate drug costs to enrollees, which may expose rebate amounts previously hidden—potentially triggering manufacturer and PBM litigation over proprietary information.
• Public reporting of aggregated PBM bid data (subsection i(2)(C)) may enable competitors to reverse-engineer pricing strategies, but also creates benchmarking pressure that could suppress PBM margins industry-wide.
• Affiliate-pharmacy monitoring (subsection j(2)(C)(iii)(III)) targets PBM self-dealing but requires item-level audits that are resource-intensive; enforcement depends on Secretary capacity and political will.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary Medicare beneficiaries and commercial plan enrollees gain transparency into drug pricing and cost-sharing, reduced hidden markups by PBMs, and enforcement mechanisms that tie plan performance to actual costs. The bill directly constrains PBM opacity and profit-taking, which have historically inflated out-of-pocket costs for patients.

Who stands to gain

• Medicare beneficiaries (lower out-of-pocket costs via reduced hidden PBM markups)
• Commercial plan sponsors (lower net drug costs via competitive bidding)
• Commercial plan enrollees (improved cost-sharing transparency)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Pharmacy Benefit Managers (PBMs), PDP sponsors (Medicare Part D plan sponsors), MA-PD plans (Medicare Advantage with drug coverage), ERISA covered plans (commercial health plans), Drug manufacturers, Pharmacies and pharmacy affiliates

Where it stands

4 cosponsors: 2 Democrats, 2 Republicans.

• Sep 14, 2026 — Introduced · Congress.gov: “Introduced in House”
• Sep 14, 2026 — Referred to House Committee on Education and Workforce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.